-- Zip（ASX：ZIP）週四向澳洲證券交易所提交的文件顯示，4月份集團整體成長動能持續強勁，美國業務總交易額（TTV）年增超過40%（以美元計）。 該公司表示，美國信貸業績符合預期，預計在第四財季將信貸支出控制在TTV的1.75%以下。 Zip重申了2026財年的業績指引，包括集團稅前折舊攤銷前現金收益（EBTDA）超過2.6億澳元，美國業務TTV同比增長超過40%（以美元計），以及集團營業利潤率超過18%。 該公司補充道，其他績效指引指標包括集團營收利率約8%，集團現金EBTDA佔TTV的比例超過1.4%，以及集團現金淨交易利潤率介於3.8%至4.2%之間。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661